Merck handed $200m in Gilead hepatitis C row
Gilead has been ordered to pay Merck $200 million in damages following a trial that found it had infringed patents covering hepatitis C treatments.
The damages award, announced on Friday, March 25, related to an earlier ruling from March 22 which found that Merck’s patents covering the active ingredient in hepatitis C drugs were valid.
The trial, which took place at the US District Court for the Northern District of California, stemmed from a 2013 lawsuit filed by Gilead.
Gilead claimed Merck’s two patents, which centre on the sofosbuvir compound, should be declared invalid before Merck claimed blockbuster drugs Harvoni (ledipasvir/sofosbuvir) and Sovaldi (sofosbuvir) infringed its patents.
Gilead said that the patents were not specific enough to cover its drugs.
Merck, which filed a counterclaim of infringement, had demanded $2 billion in damages and royalties related to sales.
The trial has yet to determine whether Gilead should be held liable for paying royalties based on infringing sales.
A spokesperson for Merck said the jury’s verdict upholds patent protection that is essential to the development of new medical treatments.
Separately, Merck recently began selling hepatitis C drug Zepatier (elbasvir and grazoprevir).
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk